PLx Pharma Inc. reported that the united states food and drug administration has accepted for review a new drug application for PL2200 Aspirin 325 mg. The company is developing PL2200 Aspirin 325 mg for sale Over-the-Counter. With the PL2200 NDA filing, a significant milestone has been reached bringing this novel first-to-market, liquid-filled aspirin product closer to commercialization. The company has elected Peter Mann to its Board of Directors. Peter Mann is a founding partner with Yellow Wood Partners, an investment firm focused on branded consumer packaged goods. Prior to Yellow Wood Partners, Peter co-founded Blacksmith Brands Inc. in 2009 and as Chairman and CEO led the acquisition of a group of brands from a major pharmaceutical company, rejuvenated them and then successfully sold the company in 2010.